MORNINGLYTE: A Phase III randomized, open-label, international, multicenter, study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to CD20 Ab plus chemotherapy in subjects with previously untreated high-tumor burden fol Image En savoir plus sur MORNINGLYTE: A Phase III randomized, open-label, international, multicenter, study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to CD20 Ab plus chemotherapy in subjects with previously untreated high-tumor burden fol
A phase 3 randomized, open-label, multicenter Study of Zanubrutinib (BGB-3111) plus anti-CD20 antibodies versus Lenalidomide plus Rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma Image En savoir plus sur A phase 3 randomized, open-label, multicenter Study of Zanubrutinib (BGB-3111) plus anti-CD20 antibodies versus Lenalidomide plus Rituximab in patients with relapsed/refractory follicular or marginal zone lymphoma
LIBERTY: Liquid biopsy to diagnose and monitor central nervous system (CNS) involvement in high-risk B cell non-Hodgkin lymphoma Image En savoir plus sur LIBERTY: Liquid biopsy to diagnose and monitor central nervous system (CNS) involvement in high-risk B cell non-Hodgkin lymphoma
